Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2023-08-23 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年半年度报告' which translates to '2023 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, accounting data, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes financial figures for the first half of 2023, management commentary, risk disclosures, and detailed business descriptions. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-23 Chinese
和元生物技术（上海）股份有限公司独立董事关于第三届董事会第九次相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement of prior approval opinions by independent directors regarding matters to be discussed at the company's third board meeting. It involves review and consent on a proposed investment and related party transaction. The content is related to board/management decisions and approvals rather than financial results, audit, or shareholder voting outcomes. The document is short (515 characters) and does not contain financial data or detailed report content. It is not an announcement of a report publication or a certification. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2023-08-23 Chinese
和元生物技术（上海）股份有限公司独立董事关于第三届董事会第九次相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's third board meeting, specifically regarding a mid-year report on the use of raised funds and approval of a related-party transaction involving an industrial investment fund. It references compliance with regulatory guidelines and company bylaws, and provides independent opinions on these matters. The document is short (863 characters) and does not contain full financial statements or detailed financial data. It is not a full interim or annual report but rather an independent opinion related to board meeting matters. This fits best under Board/Management Information (MANG), as it concerns board meeting opinions and approvals on company matters.
2023-08-23 Chinese
关于2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and actual use of funds raised by the company in the first half of 2023. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and provides specific financial figures on the amount raised, usage, balances, and management of the raised funds. The document is titled as a "专项报告" (special report) on the half-year fundraising funds storage and usage. It contains substantive financial data and analysis related to the use of capital raised, including investment projects and cash management. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report publication, nor is it a full annual or interim financial report. Therefore, the appropriate classification is CAP.
2023-08-23 Chinese
关于参与设立产业投资基金暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by a company about its participation in establishing an industrial investment fund and related party transactions. It includes investment details, decision and approval procedures, risk analysis, and opinions from the board, supervisory committee, independent directors, and the sponsor institution. The content focuses on a specific capital investment and related party transaction rather than financial results, management changes, or regulatory certifications. It is not a full financial report, earnings release, or management discussion. The document is an official announcement about a capital investment and financing activity by the company. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6645 characters) and detailed content support this classification with high confidence.
2023-08-23 Chinese
关于变更公司注册资本及修订公司章程并办理工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding changes in its registered capital and amendments to its articles of association. It details board meeting decisions, share option exercises, capital increase, and corresponding amendments to the company charter. The document is relatively short (1839 characters) and serves as a formal public notice of these corporate actions rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or detailed management discussion. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-08-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.